TY - JOUR
T1 - Implantable Peripheral Nerve Stimulation for Peripheral Neuropathic Pain
T2 - A Systematic Review of Prospective Studies
AU - Char, Steven
AU - Jin, Max Y.
AU - Francio, Vinicius Tieppo
AU - Hussain, Nasir
AU - Wang, Eric J.
AU - Morsi, Mahmoud
AU - Orhurhu, Vwaire
AU - Prokop, Larry J.
AU - Fink, Adam
AU - D’Souza, Ryan S.
N1 - Funding Information:
No funding was received for this study or the publication of this article.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/10
Y1 - 2022/10
N2 - Peripheral nerve stimulation (PNS) has been utilized for over 50 years with accumulating evidence of efficacy in a variety of chronic pain conditions. The level and strength of evidence supporting the use of PNS for peripheral neuropathic pain remains unclear. The purpose of this review is to synthesize data from prospective studies on the efficacy of PNS for neuropathic pain as it pertains to pain intensity, neurological deficits/neuropathy (e.g., weakness, sensory deficits, gait/balance), and other secondary outcomes (quality of life, satisfaction, emotional functioning, and adverse events). In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, this review identified articles from MEDLINE(R), EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. Overall, per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria, pooled results demonstrate very low quality or low quality of evidence supporting modest to substantial improvement in pain and neurological function after PNS implantation for treatment of peripheral neuropathic pain. PNS for phantom limb pain was the only indication that had moderate level evidence. Future prospective and well-powered studies are warranted to assess the efficacy of PNS for peripheral neuropathic pain.
AB - Peripheral nerve stimulation (PNS) has been utilized for over 50 years with accumulating evidence of efficacy in a variety of chronic pain conditions. The level and strength of evidence supporting the use of PNS for peripheral neuropathic pain remains unclear. The purpose of this review is to synthesize data from prospective studies on the efficacy of PNS for neuropathic pain as it pertains to pain intensity, neurological deficits/neuropathy (e.g., weakness, sensory deficits, gait/balance), and other secondary outcomes (quality of life, satisfaction, emotional functioning, and adverse events). In compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, this review identified articles from MEDLINE(R), EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. Overall, per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria, pooled results demonstrate very low quality or low quality of evidence supporting modest to substantial improvement in pain and neurological function after PNS implantation for treatment of peripheral neuropathic pain. PNS for phantom limb pain was the only indication that had moderate level evidence. Future prospective and well-powered studies are warranted to assess the efficacy of PNS for peripheral neuropathic pain.
KW - chronic pain
KW - neuromodulation
KW - peripheral nerve stimulator
KW - peripheral neuropathy
UR - http://www.scopus.com/inward/record.url?scp=85140653201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140653201&partnerID=8YFLogxK
U2 - 10.3390/biomedicines10102606
DO - 10.3390/biomedicines10102606
M3 - Review article
C2 - 36289867
AN - SCOPUS:85140653201
SN - 2227-9059
VL - 10
JO - Biomedicines
JF - Biomedicines
IS - 10
M1 - 2606
ER -